Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74


Biosynthesis, characterization, and evaluation of bioactivities of leaf extract-mediated biocompatible gold nanoparticles from Alternanthera bettzickiana.

M N, V N K, V DR, A P.

Biotechnol Rep (Amst). 2018 Jun 22;19:e00268. doi: 10.1016/j.btre.2018.e00268. eCollection 2018 Sep.


Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial.

Richardson PG, Schlossman RL, Roy AN, Panneerselvam A, Acharyya S, Sopala M, Lonial S.

Br J Haematol. 2018 Jun;181(5):628-636. doi: 10.1111/bjh.15248. Epub 2018 May 17.


ECG in hyperkalaemia.

Panneerselvam A.

Postgrad Med J. 2018 Sep;94(1115):537. doi: 10.1136/postgradmedj-2018-135735. Epub 2018 Apr 26. No abstract available.


Fermentation of dihydroxyacetone by engineered Escherichia coli and Klebsiella variicola to products.

Wang L, Chauliac D, Rhee MS, Panneerselvam A, Ingram LO, Shanmugam KT.

Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):4381-4386. doi: 10.1073/pnas.1801002115. Epub 2018 Apr 9.


Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent.

Richardson P, Roy A, Acharyya S, Panneerselvam A, Mendelson E, Günther A, Lonial S, Einsele H.

Expert Rev Hematol. 2017 Oct;10(10):933-939. doi: 10.1080/17474086.2017.1369399. Epub 2017 Sep 25.


Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.

Velusamy T, Panneerselvam AS, Purushottam M, Anusuyadevi M, Pal PK, Jain S, Essa MM, Guillemin GJ, Kandasamy M.

Oxid Med Cell Longev. 2017;2017:3279061. doi: 10.1155/2017/3279061. Epub 2017 Jan 12. Review.


Teneligliptin in management of type 2 diabetes mellitus.

Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC.

Diabetes Metab Syndr Obes. 2016 Aug 16;9:251-60. doi: 10.2147/DMSO.S106133. eCollection 2016. Review.


REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis.

Bracarda S, Rottey S, Bahl A, Eichelberg C, Mellado B, Mangel L, Cattaneo A, Panneerselvam A, Grünwald V.

Future Oncol. 2015;11(21):2893-903. doi: 10.2217/fon.15.241. Epub 2015 Sep 17.


Optimization of sporicidal activity and environmental Bacillus endospores decontamination by biogenic silver nanoparticle.

Gopinath PM, Dhanasekaran D, Ranjani A, Thajuddin N, Akbarsha MA, Velmurugan M, Panneerselvam A.

Future Microbiol. 2015;10(5):725-41. doi: 10.2217/fmb.14.150.


Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.

Lombard-Bohas C, Yao JC, Hobday T, Van Cutsem E, Wolin EM, Panneerselvam A, Stergiopoulos S, Shah MH, Capdevila J, Pommier R.

Pancreas. 2015 Mar;44(2):181-9. doi: 10.1097/MPA.0000000000000262.


Device closure of complex ASD--safe and feasible.

Panneerselvam A.

Indian Heart J. 2014 Jul-Aug;66(4):485. doi: 10.1016/j.ihj.2014.05.004. Epub 2014 Jun 3. No abstract available.


Glucose modulates Pax6 expression through the JNK/p38 MAP kinase pathway in pancreatic beta-cells.

Balakrishnan S, Sadasivam M, Kannan A, Panneerselvam A, Prahalathan C.

Life Sci. 2014 Jul 25;109(1):1-7. doi: 10.1016/j.lfs.2014.06.009. Epub 2014 Jun 20.


Bilateral coronary ostial lesions in cardiovascular syphilis treated by means of percutaneous coronary stenting.

Shankarappa RK, Moorthy N, Panneerselvam A, Karur S, Dwarakaprasad R, Nanjappa MC.

Tex Heart Inst J. 2013;40(5):630-2. No abstract available.


Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.

Pritchard KI, Burris HA 3rd, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M.

Clin Breast Cancer. 2013 Dec;13(6):421-432.e8. doi: 10.1016/j.clbc.2013.08.011.


Potential of ozonolysis as a pretreatment for energy grasses.

Panneerselvam A, Sharma-Shivappa RR, Kolar P, Ranney T, Peretti S.

Bioresour Technol. 2013 Nov;148:242-8. doi: 10.1016/j.biortech.2013.08.129. Epub 2013 Aug 30.


Hydrolysis of ozone pretreated energy grasses for optimal fermentable sugar production.

Panneerselvam A, Sharma-Shivappa RR, Kolar P, Clare DA, Ranney T.

Bioresour Technol. 2013 Nov;148:97-104. doi: 10.1016/j.biortech.2013.08.119. Epub 2013 Aug 26.


Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.

Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahmoud T, Piccart M.

Eur J Cancer. 2013 Aug;49(12):2621-32. doi: 10.1016/j.ejca.2013.04.011. Epub 2013 Jun 1.


Optimization of Antimicrobial Production by a Marine Actinomycete Streptomyces afghaniensis VPTS3-1 Isolated from Palk Strait, East Coast of India.

Vijayakumar R, Panneerselvam K, Muthukumar C, Thajuddin N, Panneerselvam A, Saravanamuthu R.

Indian J Microbiol. 2012 Jun;52(2):230-9. doi: 10.1007/s12088-011-0138-x. Epub 2011 Jan 25.


Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2.

Noguchi S, Masuda N, Iwata H, Mukai H, Horiguchi J, Puttawibul P, Srimuninnimit V, Tokuda Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Noh WC, Nakayama T, Ohno S, Rai Y, Park BW, Panneerselvam A, El-Hashimy M, Taran T, Sahmoud T, Ito Y.

Breast Cancer. 2014 Nov;21(6):703-14. doi: 10.1007/s12282-013-0444-8. Epub 2013 Feb 13.


Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.

van den Eertwegh AJ, Karakiewicz P, Bavbek S, Rha SY, Bracarda S, Bahl A, Ou YC, Kim D, Panneerselvam A, Anak O, Grünwald V.

Urology. 2013 Jan;81(1):143-9. doi: 10.1016/j.urology.2012.09.019.


Supplemental Content

Loading ...
Support Center